Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
XENE

Xenon Pharmaceuticals (XENE) stock: insider trades, news & valuation

Health Care · Net selling
Close · Oct 9, 2026 $36.44 +0.8% on the day -11.7% over 12 months 52-week range $36.16 – $70.96

Share price and insider trades

XENE closeInsider buyInsider sale
20406080NovDecJan 2026FebMarAprMayJunJulAugSepOctSold $4,366 on 2025-11-28 · Ian MortimerSold $133,488 on 2026-06-05 · Gary Patou, Gillian CannonSold $425,849 on 2026-08-28 · Christopher John KenneySold $495,207 on 2025-12-08 · Ian MortimerSold $555,614 on 2026-03-13 · Andrea Difabio, Christopher John Kenney, Ian MortimerSold $640,600 on 2026-08-11 · Steven GannonSold $647,306 on 2025-12-05 · Ian MortimerSold $1,000,651 on 2026-03-10 · Andrea Difabio, Christopher John Kenney, Ian MortimerBought $1,681,140 on 2026-09-30 · Ian Mortimer, Thomas Patrick KellySold $1,777,093 on 2026-01-02 · Ian MortimerSold $16,289,143 on 2026-03-09 · Ian Mortimer
Bought, 12 months$1.7M
Sold, 12 months$22.0M
Insiders buying2
Insiders selling6

Xenon Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 2 insiders bought $1.7M and 6 sold $22.0M of XENE stock on the open market.

XENE insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $2.2M sold (5 trades)Q4 2025Q1 2026: $19.6M sold (17 trades)Q1 2026Q2 2026: $133K sold (2 trades)Q2 2026Q3 2026: $1.7M bought (2 trades)$1.7MQ3 2026: $1.1M sold (3 trades)Q3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026$1.7M2$1.1M3
Q2 2026—0$133K2
Q1 2026—0$19.6M17
Q4 2025—0$2.2M5

Valuation, profit and volume

Pick score 55/100
P/E (trailing)n/aSector median 24.7
Market value$3.53BBiotechnology
Profit margin0.0%Revenue growth —
Volume vs. 50-day1.4×Last 5 sessions
Insiders' paper profit−$41KOn all tracked purchases -2.5%

Summary

Over the past 12 months, 2 Xenon Pharmaceuticals Inc. insiders reported open-market purchases totaling $1.7M, while 6 insiders reported sales totaling $22.0M. 26 of 27 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

XENE stock news and SEC filings

Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Oct 1SEC Ian MortimerCEO, President Buy 30,00049,923 held (+151%) $37.38 $1.1M -2.5% —
Oct 1SEC Thomas Patrick KellyCFO Buy 15,000new position $37.32 $560K -2.3% —
Aug 31SEC Christopher John KenneyChief Medical Officer Sell Plan 6,368702 held (−90%) $60.17 $383K -39.4% —
Aug 31SEC Christopher John KenneyChief Medical Officer Sell Plan 7002 held (−100%) $60.98 $43K -40.2% —
Aug 13SEC Steven GannonDirector Sell 10,0001,870 held (−84%) $64.06 $641K -43.1% —
Jun 8SEC Gary PatouDirector Sell Plan 1,32224,896 held (−5%) $53.14 $70K -31.4% —
Jun 8SEC Gillian CannonDirector Sell Plan 1,1901,455 held (−45%) $53.14 $63K -31.4% —
Mar 13SEC Ian MortimerCEO, President Sell Plan 7,30819,923 held (−27%) $55.23 $404K -34.0% —
Mar 13SEC Christopher John KenneyChief Medical Officer Sell Plan 1,4107,069 held (−17%) $55.23 $78K -34.0% —
Mar 13SEC Andrea DifabioGeneral Counsel Sell Plan 1,3427,301 held (−16%) $55.23 $74K -34.0% —
Mar 11SEC Ian MortimerCEO, President Sell Plan 65,0006,000 held (−92%) $62.06 $4.0M -41.3% —
Mar 11SEC Ian MortimerCEO, President Sell Plan 61,6526,000 held (−91%) $60.08 $3.7M -39.3% —
Mar 11SEC Ian MortimerCEO, President Sell Plan 43,34872,652 held (−37%) $59.26 $2.6M -38.5% —
Mar 11SEC Ian MortimerCEO, President Sell Plan 31,69427,515 held (−54%) $59.88 $1.9M -39.1% —
Mar 11SEC Ian MortimerCEO, President Sell Plan 21,5156,000 held (−78%) $60.49 $1.3M -39.8% —
Mar 11SEC Ian MortimerCEO, President Sell Plan 21,79159,209 held (−27%) $58.81 $1.3M -38.0% —
Mar 11SEC Ian MortimerCEO, President Sell Plan 12,47918,521 held (−40%) $59.50 $743K -38.8% —
Mar 11SEC Ian MortimerCEO, President Sell Plan 11,26914,731 held (−43%) $60.11 $677K -39.4% —
Mar 11SEC Ian MortimerCEO, President Sell Plan 10,0728,449 held (−54%) $60.47 $609K -39.7% —
Mar 11SEC Christopher John KenneyChief Medical Officer Sell Plan 2,7714,729 held (−37%) $60.11 $167K -39.4% —
Mar 11SEC Andrea DifabioGeneral Counsel Sell Plan 2,6074,893 held (−35%) $60.11 $157K -39.4% —
Mar 11SEC Ian MortimerCEO, President Sell Plan 2,4496,000 held (−29%) $61.26 $150K -40.5% —
Jan 2SEC Ian MortimerCEO, President Sell Plan 37,9388,062 held (−82%) $44.40 $1.7M -17.9% —
Jan 2SEC Ian MortimerCEO, President Sell Plan 2,0626,000 held (−26%) $44.93 $93K -18.9% —
Dec 9SEC Ian MortimerCEO, President Sell Plan 14,37516,830 held (−46%) $45.03 $647K -19.1% —
Dec 9SEC Ian MortimerCEO, President Sell Plan 8,8208,010 held (−52%) $45.59 $402K -20.1% —
Dec 9SEC Ian MortimerCEO, President Sell Plan 2,0106,000 held (−25%) $46.32 $93K -21.3% —
Dec 3SEC Ian MortimerCEO, President Sell Plan 9731,205 held (−0%) $45.01 $4K -19.0% —
Oct 1SEC Ian MortimerCEO, CFO Sell Plan 25,00031,302 held (−44%) $40.16 $1.0M -9.3% —

Insiders at Xenon Pharmaceuticals Inc.

InsiderBoughtSoldLast filingScore
Ian MortimerCEO, President $1.1M $21.3M Oct 1, 2026 —
Thomas Patrick KellyCFO $560K — Oct 1, 2026 —
Christopher John KenneyChief Medical Officer — $670K Aug 31, 2026 —
Steven GannonDirector — $641K Aug 13, 2026 —
Andrea DifabioGeneral Counsel — $231K Mar 13, 2026 —
Gary PatouDirector — $70K Jun 8, 2026 —
Gillian CannonDirector — $63K Jun 8, 2026 —

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • SLBTSL Science Holding Ltd$10329.90B bought
  • KODKodiak Sciences Inc.$157M bought
  • ADRXADARx Pharmaceuticals, Inc.$87.7M bought
  • ATTOAttovia Therapeutics, Inc.$72.9M bought
  • MPLTMapLight Therapeutics, Inc.$65.5M bought
  • AVRAnteris Technologies Global Corp.$40.4M bought

XENE stock: common questions

Are Xenon Pharmaceuticals Inc. insiders buying XENE stock?

In the past 12 months, 2 insiders reported open-market purchases of XENE worth $1.7M. The latest was CEO, President Ian Mortimer bought $1.1M of XENE at $37.38 — first open-market purchase in our records; raises the stake by 151%.

Are Xenon Pharmaceuticals Inc. insiders selling XENE stock?

6 insiders reported sales worth $22.0M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is XENE's 52-week range?

Over the past year XENE has traded between $36.16 and $70.96. It last closed at $36.44 on Oct 9, 2026.